PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsUrinary bladder neoplasms
MeSH D001749 - urinary bladder neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D001745:Urinary bladder diseases
66 Companies
15 Drugs
$
Success rate
D014571:Urologic neoplasms
5 Companies
5 Drugs
$
Success rate
D001749: 
Urinary bladder neoplasms
53 Companies
14 Drugs
$
Success rate
D000093284:Non-muscle invasive bladder neoplasms
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCarboplatin Carboplatin  2005-09-21   
Doxorubicin Doxorubicin  1995-07-28   
Etoposide Etoposide  1994-02-10   
Doxorubicin Myocet (previously Myocet)  2000-07-13   
Oxaliplatin Oxaliplatin  2009-08-07   
Thiotepa Thiotepa  2001-04-20   
Etoposide Toposar  1995-02-27   
Cisplatin Cisplatin  2000-05-16   
Novast LaboratoriesCarboplatin Carboplatin  2017-04-26   
Oxaliplatin Oxaliplatin  2018-10-16   
MylanCarboplatin Carboplatin  2007-04-24   
Doxorubicin Doxorubicin  2011-10-28   
Etoposide Etoposide  2001-09-19   
Oxaliplatin Oxaliplatin  2012-08-07   
Cisplatin Cisplatin  2012-04-18   
NATCO PharmaCarboplatin Carboplatin  2012-05-29   
RocheAtezolizumab Tecentriq  2017-09-20 $4,406.336 M Q4/22-Q3/23 
CiplaCarboplatin Carboplatin  2006-01-27   
SandozCarboplatin Carboplatin  2005-03-18   
Oxaliplatin Oxaliplatin  2009-08-07   
SanofiOxaliplatin Eloxatin  2002-08-09   
Merck & CoPembrolizumab Keytruda  2014-09-04 $28,253 M Q4/23-Q3/24 
PfizerDoxorubicin Adriamycin  1991-01-30   
Doxorubicin Doxorubicin  1982-01-01   
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
71%
79/112
Phase 2
30%
52/172
Phase 3
30%
24/79
Approved: 13Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Carboplatin,
Cisplatin,
Doxorubicin,
Doxorubicin hydrochloride,
Etoposide
Mylan
Carboplatin
Roche
Atezolizumab,
Sacituzumab,
Transplatin,
Ado-trastuzumab emtansine,
Magrolimab,
Tiragolumab,
Nepidermin,
Q2w,
RO7122290,
Arm1,
Beam,
Arm2,
Docetaxol,
Bdb001,
Tcz
Sandoz
Carboplatin,
Tbo-filgrastim,
Lenograstim,
Gcsf
Sanofi
Oxaliplatin,
Transplatin,
Bevifimod,
Larotaxel,
Gemcis,
Docetaxol,
Taxane
Merck & Co
Pembrolizumab,
Sacituzumab,
Transplatin,
Tbo-filgrastim,
Albumin,
Entinostat,
Epacadostat,
Aglatimagene besadenovec,
Begelomab,
Lenograstim,
Patritumab,
Patritumab deruxtecan,
Sodium chloride,
Sodium lactate,
Bevifimod,
Favezelimab,
Vibostolimab,
VOFATAMAB,
Microcrystalline cellulose,
Mk-4280,
Caelyx,
Diluent,
AN0025,
Doxorubin,
Mk3475,
Q2w,
Vp16,
Gcsf,
Mmc,
Neulastim,
Sbrt,
Arm1,
Beam,
Gemcis,
Hydroxydaunomycin,
Pcd,
Arm2,
Bolus,
Docetaxol,
E7046,
MRX0518,
DPX,
Mephedrone,
Skb264
Pfizer
Doxorubicin,
Doxorubicin hydrochloride,
Transplatin,
Sasanlimab,
Bevifimod,
Edodekin alfa,
Pd0332991,
Sbrt,
Arm1,
Gemcis,
Pcd,
Arm2,
Evidence
Dr Reddys Laboratories
Doxorubicin,
Doxorubicin hydrochloride
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use